CORBF — Global Cord Blood Share Price
Last trade - 00:00- $140.61m
- -$772.78m
- CNY1.24bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.21 | ||
| Price to Tang. Book | 0.21 | ||
| Price to Free Cashflow | 1.73 | ||
| Price to Sales | 0.82 | ||
| EV to EBITDA | -8.57 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.72% | ||
| Return on Equity | 10.82% | ||
| Operating Margin | 48.97% | ||
Financial Summary
| Year End 31st Mar | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CNYm | 936.77 | 986.75 | 1,221.46 | 1,159.64 | 1,243.26 | n/a | n/a | 10.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +22.79 | +20.67 | +61.52 | +7.97 | -1.41 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Global Cord Blood Corporation is a provider of cord blood banking services in China. The Company and its subsidiaries are principally engaged in the provision of umbilical cord blood storage and ancillary services in the People's Republic of China. It provides cord blood testing, processing and storage services under the direction of subscribers for a cord blood processing fee and a storage fee. It also tests, processes and stores donated cord blood, and provides matching services to the public for a fee. The Company provides cord blood processing and storage services for expectant parents interested in capturing the opportunities made available by evolving medical treatments and technologies, such as cord blood transplants. It also preserves cord blood units donated by the public; provides matching services on such donated units, and delivers matching units to patients in need of transplants.
Directors
- Ting Zheng CHM (49)
- Albert Chen CFO (45)
- Rui Arashiyama CEX (62)
- Xin Xu CTO (67)
- Ping Xu NED (42)
- Mark Chen NID (53)
- Siu Chuen Cheng NID (47)
- Jack Chow NID (60)
- Ken Lu NID (57)
- Jennifer Weng NID (53)
- Last Annual
- March 31st, 2022
- Last Interim
- March 31st, 2022
- Incorporated
- April 10th, 2006
- Public Since
- November 19th, 2009
- No. of Employees
- 1,202
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 133,914,711
- Address
- 48 Fl., Bank Of China Tower, 000000
- Web
- https://globalcordbloodcorporation.com/
- Phone
- +852 null36058180
- Auditors
- KPMG
Upcoming Events for CORBF
Similar to CORBF
4Cable TV International
Pink Sheets on Nasdaq
Abattis Bioceuticals
Pink Sheets on Nasdaq
Accelera Innovations
Pink Sheets on Nasdaq
Quantum Medical Transport
Pink Sheets on Nasdaq
Aesthetic Medical International Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 20:51 UTC, shares in Global Cord Blood are trading at $1.05. This share price information is delayed by 15 minutes.
Shares in Global Cord Blood last closed at $1.05 and the price had moved by -16% over the past 365 days. In terms of relative price strength the Global Cord Blood share price has underperformed the S&P500 Index by -21.52% over the past year.
The overall consensus recommendation for Global Cord Blood is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreGlobal Cord Blood does not currently pay a dividend.
Global Cord Blood does not currently pay a dividend.
Global Cord Blood does not currently pay a dividend.
To buy shares in Global Cord Blood you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.05, shares in Global Cord Blood had a market capitalisation of $140.61m.
Here are the trading details for Global Cord Blood:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CORBF
Based on an overall assessment of its quality, value and momentum Global Cord Blood is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Global Cord Blood is $15.00. That is 1328.57% above the last closing price of $1.05.
Analysts covering Global Cord Blood currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Global Cord Blood. Over the past six months, its share price has underperformed the S&P500 Index by -13.05%.
As of the last closing price of $1.05, shares in Global Cord Blood were trading -17.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Global Cord Blood PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Global Cord Blood's management team is headed by:
- Ting Zheng - CHM
- Albert Chen - CFO
- Rui Arashiyama - CEX
- Xin Xu - CTO
- Ping Xu - NED
- Mark Chen - NID
- Siu Chuen Cheng - NID
- Jack Chow - NID
- Ken Lu - NID
- Jennifer Weng - NID